Testing a new liquid form of nintedanib for IPF
Part of Lungs & breathing clinical trials.
This trial tests a liquid version of the medication nintedanib (AP02) to see if it is safe and works well for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and have not taken nintedanib or pirfenidone recently, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 40 years or older
- You have been diagnosed with IPF within the last 5 years
- Your lung function tests show a certain level of breathing ability (FVC at least 45% of normal, and DLCO between 30-80% of normal)
- You have not taken nintedanib or pirfenidone in the last 3 months
- You do not have serious heart, bleeding, liver, or kidney problems
- You are willing to use effective birth control if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled form of nintedanib (a drug that helps slow lung scarring) for people with idiopathic pulmonary fibrosis (IPF). It may be an option for those newly diagnosed or already on stable treatment.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
This trial tests an inhaled drug called LTI-03 to see if it can help people with idiopathic pulmonary fibrosis (IPF). It may be an option for those with moderate lung function who are stable on their current treatment.
This trial tests a new oral medication, HSK50042, for people with Idiopathic Pulmonary Fibrosis (IPF). It aims to see if the drug can help slow lung function decline, and is looking for patients who meet specific lung function criteria and are either not currently on anti-fibrotic therapy or on a stable dose.
This trial tests a new drug called TDI01 to see if it helps people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. You may qualify if you have a confirmed IPF diagnosis and your lung function is stable enough.
This trial tests whether adding dextromethorphan (a common cough medicine) to nintedanib (a lung-fibrosis drug) helps slow lung damage in people with idiopathic pulmonary fibrosis (IPF)—a condition where lung tissue becomes scarred and stiff. The study lasts 12 weeks plus one follow-up visit.
Hear when a new Idiopathic Pulmonary Fibrosis (IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.